You are here

Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA189537-01
Agency Tracking Number: R41CA189537
Amount: $219,130.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
FRAMINGHAM, MA 01701-3880
United States
DUNS: 962728304
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (203) 932-5711
Business Contact
Phone: (508) 877-4522
Research Institution
NEW HAVEN, CT 06510-3209
United States

 () -
 Nonprofit college or university

DESCRIPTION (provided by applicant): Cisplatin is a cornerstone therapy for a number of cancers including testicular, bladder, ovarian and lung. It is also used to treat cancers in children. In all cases there is a high incidence of acute kidney injury (AKI) that can also lead to later stage kidney damage. This risk limits its use. We have found in pilot studies that renalase, or peptide fragments of renalase, offers the innovative potential to limit or treat this damage, thereby improving the safety and utility of cisplatin and potentially resulting in better outcomes. This proposal will prioritize the best clinical candidate for later stage development and proof of concept clinical trials in patients. Renalase, a secreted flavin adenine dinucleotide (FAD) dependent amine oxidase, is synthesized by the renal proximal tubule, secreted in blood, preferentially metabolizes epinephrine, continuously excreted in urine in the basal state. We have shown renalase deficiency (renalase KO vs Wild type [WT] mice

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government